- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...

Fulton, MD, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Arms Cyber today announced the launch of the Shield Partner Program, a bold ...

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to ...

WAYNE, Pa., April 13, 2021 /PRNewswire/ — Evolve IP (R), a leading international service provider of Work AnywhereTM solutions, today announced that Paradigm Technology Group, an IT services ...

WASHINGTON, May 2, 2024 /PRNewswire/ -- The National Association of Investment Companies (NAIC) is pleased to announce the 2024 cohort of Paradigm Changers interns. Launched in 2021, NAIC's Paradigm ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...